Iovance Biotherapeutics announced that it has received accelerated FDA approval for its tumor-infiltrating lymphocytes (TIL)** lifileucel, becoming the world's first marketed TIL cell for advanced melanoma**, which has attracted widespread attention in the biomedical field. It is reported that the price of the ** is US$515,000, equivalent to about 3.7 million yuan.
TIL** is a personalized immuno** that attacks tumor cells by extracting and expanding tumor-infiltrating lymphocytes (TILs) from the patient's own tumor tissue and then infusing them back into the patient. This has shown potential in cancers such as melanoma, which is a type of cancer that is more sensitive to immunity.
The FDA's accelerated approval is based on the results of a single-arm study evaluating the efficacy and safety of lifileucel in patients with advanced melanoma. The results showed that patients who received lifileucel** experienced a significant increase in overall survival and achieved long-term tumor control in some patients.
Although Lifileucel is priced higher, this may reflect its R&D and production costs to some extent, given its personalized preparation process and unique efficacy. In addition, with the continuous development and optimization of cell** technology, more cells** with better efficacy and lower cost may be available in the future, providing more ** options for cancer patients.
In summary, Iovance Biotherapeutics' Lifileucel offers a new option for patients with advanced melanoma. Although its ** is high, its unique efficacy and personalized preparation process make this ** have an important position in the field of biomedicine. As technology continues to advance, we look forward to more similar innovations** in the future to bring better outcomes and quality of life to cancer patients."